医学
美罗华
肉芽肿伴多发性血管炎
显微镜下多血管炎
免疫学
狼疮性肾炎
膜性肾病
抗中性粒细胞胞浆抗体
肾小球膜炎
CD20
快速进行性肾小球肾炎
血管炎
内科学
抗体
肾小球肾炎
疾病
肾
作者
Andrea Kattah,Fernando C. Fervenza
摘要
The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.
科研通智能强力驱动
Strongly Powered by AbleSci AI